MSB 7.69% $1.19 mesoblast limited

Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment, page-368

  1. 7,518 Posts.
    lightbulb Created with Sketch. 6772
    Yeah, I hear your skepticism and its well founded, the FDA are shocking:

    https://www.sciencemag.org/news/2018/07/hidden-conflicts-pharma-payments-fda-advisers-after-drug-approvals-spark-ethical

    https://www.pogo.org/investigation/2020/10/some-fda-advisors-tapped-to-review-coronavirus-vaccines-received-payments-from-vaccine-companies/

    But ultimately, the figures speak for themselves. The FDA doesn't knock back NIH backed trials. This decision is out of their hands almost. If the rigidly professional trial shows efficacy, its literally indisputable. Not just a gold standard RCT, but fully independently run. Not even political coercion could stop a COVID-19 relatd ARDS cure from being adopted.

    Holding your stock is now back to the simple decision of whether you believe in the science or not. Why most of us are originally invested. Easy for me as I've researched them to death having had both successful tenocyte (Orthocell) and mesenchymal (Regeneus) stem cell treatments and believe MSB is about to pave the way for some brilliant Aussie bio-techs. It was always going to be an uphill task of course.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.19
Change
0.085(7.69%)
Mkt cap ! $1.358B
Open High Low Value Volume
$1.10 $1.20 $1.09 $13.21M 11.37M

Buyers (Bids)

No. Vol. Price($)
1 15000 $1.19
 

Sellers (Offers)

Price($) Vol. No.
$1.19 75212 5
View Market Depth
Last trade - 16.10pm 12/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.